Home・Aktien・AstraZeneca PLC

AstraZeneca PLC

Geschlossen

Branche Gesundheitswesen

12,632 0.45

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12626

Max

12668

Schlüsselkennzahlen
By Trading Economics
Einkommen	-252M 1.9B
Verkäufe	258M 13B
KGV Branchendurchschnitt	38.58 103.001
EPS	1.98
Gewinnspanne	14.894
EBITDA	-349M 4.1B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+5.83 upside

Dividenden
By Dow Jones
Nächste Dividendenausschüttung	9. Sept. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	16M 205B
Vorheriger Eröffnungskurs	12631.55
Vorheriger Schlusskurs	12632

Nachrichtenstimmung

By Acuity

61%

39%

296 / 365 Ranking in Healthcare

AstraZeneca PLC Chart

Ähnliche Nachrichten

25. Juli 2024, 09:17 UTC

Ergebnisse

AstraZeneca Raises Guidance After Results Beat Market Expectations -- Update

25. Juli 2024, 06:48 UTC

Ergebnisse

AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations

12. Juli 2024, 19:57 UTC

Wichtige Markttreiber

Instil Bio Shares Surge Following Rental Agreement with AstraZeneca

5. Sept. 2024, 13:00 UTC

AstraZeneca PLC Prognose

Kursziel

By TipRanks

5.83% Vorteil

12-Monats-Prognose

Durchschnitt 13,271.67 GBX 5.83%

Hoch 15,000 GBX

Tief 11,000 GBX

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AstraZeneca PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

15 ratings

Buy

Halten

Sell

Basierend auf 15 Analysten, die in den letzten 3 Monaten Aktienbewertungen für AstraZeneca PLC – Dist abgegeben haben.

Stimmung

By Acuity

296 / 365 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

Über AstraZeneca PLC

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.